- Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy, or other investigational therapy for at least 2 weeks (3 weeks for myelosuppressive agents) prior to study enrollment, and have recovered from the acute effects of therapy. At the discretion of the investigator, patients with prostate cancers progressing under LHRH agonists therapy, and patients with adrenal carcinomas using mitotan, may have that treatment continued while receiving study drug.